Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,965,076 | $1,206,929 | $659,862 | $483,631 |
| - Cash | $222,503 | $286,326 | $28,003 | $31,340 |
| + Debt | $317,763 | $308,142 | $2,188 | $2,614 |
| Enterprise Value | $2,060,336 | $1,228,745 | $634,047 | $454,905 |
| Revenue | $336,888 | $186,374 | $77,062 | $19,138 |
| % Growth | 80.8% | 141.8% | 302.7% | – |
| Gross Profit | $255,245 | $139,335 | $64,688 | $17,235 |
| % Margin | 75.8% | 74.8% | 83.9% | 90.1% |
| EBITDA | -$48,972 | -$136,490 | -$122,854 | -$65,386 |
| % Margin | -14.5% | -73.2% | -159.4% | -341.7% |
| Net Income | -$87,942 | -$163,415 | -$135,665 | -$83,988 |
| % Margin | -26.1% | -87.7% | -176% | -438.9% |
| EPS Diluted | -1.85 | -4 | -4.02 | -2.77 |
| % Growth | 53.8% | 0.5% | -45.1% | – |
| Operating Cash Flow | $10,325 | -$70,944 | -$120,136 | -$132,758 |
| Capital Expenditures | -$993 | -$20,109 | -$278 | -$19,024 |
| Free Cash Flow | $9,332 | -$91,053 | -$120,414 | -$151,782 |